STOCK TITAN

Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Positive)

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas has acquired 647,809 common shares valued at $425,000 through six transactions between December 20, 2024, and January 17, 2025. Following these purchases, Siokas's beneficial ownership in the company has increased to 4,164,789 common shares.

The CEO expressed enthusiasm about the company's future prospects and highlighted his continued commitment, noting his total personal investment of over $17 million since the company's inception. Siokas emphasized that Cosmos Health is at a transformative moment, focusing on advancing their strategy, driving projects forward, and expanding their brands globally.

Cosmos Health (NASDAQ:COSM) ha annunciato che il CEO Greg Siokas ha acquisito 647.809 azioni ordinarie del valore di $425.000 attraverso sei transazioni tra il 20 dicembre 2024 e il 17 gennaio 2025. Dopo questi acquisti, la partecipazione beneficiale di Siokas nella società è aumentata a 4.164.789 azioni ordinarie.

Il CEO ha espresso entusiasmo riguardo alle prospettive future della società e ha sottolineato il suo continuo impegno, notando il suo investimento personale totale di oltre $17 milioni dalla fondazione dell'azienda. Siokas ha evidenziato che Cosmos Health si trova in un momento di trasformazione, concentrandosi sull'avanzamento della loro strategia, sull'avanzamento dei progetti e sull'espansione dei loro marchi a livello globale.

Cosmos Health (NASDAQ:COSM) anunció que el CEO Greg Siokas ha adquirido 647,809 acciones comunes valoradas en $425,000 a través de seis transacciones entre el 20 de diciembre de 2024 y el 17 de enero de 2025. Tras estas compras, la propiedad beneficiosa de Siokas en la empresa ha aumentado a 4,164,789 acciones comunes.

El CEO expresó entusiasmo por las perspectivas futuras de la empresa y destacó su continuo compromiso, señalando su inversión personal total de más de $17 millones desde la creación de la empresa. Siokas enfatizó que Cosmos Health se encuentra en un momento transformador, centrado en avanzar en su estrategia, impulsar proyectos y expandir sus marcas globalmente.

코스모스 헬스 (NASDAQ:COSM)는 CEO 그렉 시오카스가 2024년 12월 20일부터 2025년 1월 17일 사이에 여섯 건의 거래를 통해 $425,000 상당의 647,809주 일반 주식을 인수했다고 발표했습니다. 이러한 매입 이후, 시오카스의 유익 소유권은 회사의 4,164,789주로 증가했습니다.

CEO는 회사의 미래 전망에 대한 열정을 표현하며 자신이 회사를 설립한 이래 총 개인 투자액이 $17 백만을 넘는다고 강조했습니다. 시오카스는 코스모스 헬스가 변혁의 순간에 있으며 전략을 발전시키고 프로젝트를 추진하며 브랜드를 세계적으로 확장하는 데 집중하고 있다고 강조했습니다.

Cosmos Health (NASDAQ:COSM) a annoncé que le PDG Greg Siokas a acquis 647 809 actions ordinaires d'une valeur de 425 000 $ à travers six transactions entre le 20 décembre 2024 et le 17 janvier 2025. Suite à ces achats, la propriété bénéficiaire de Siokas dans l'entreprise a augmenté à 4 164 789 actions ordinaires.

Le PDG a exprimé son enthousiasme concernant les perspectives d'avenir de l'entreprise et a souligné son engagement continu, notant son investissement personnel total de plus de 17 millions $ depuis la création de l'entreprise. Siokas a souligné que Cosmos Health se trouve dans un moment de transformation, se concentrant sur l'avancement de leur stratégie, le développement des projets et l'expansion de leurs marques à l'échelle mondiale.

Cosmos Health (NASDAQ:COSM) gab bekannt, dass CEO Greg Siokas 647.809 Stammaktien im Wert von $425.000 durch sechs Transaktionen zwischen dem 20. Dezember 2024 und dem 17. Januar 2025 erworben hat. Nach diesen Käufen hat sich Siokas' wirtschaftlicher Anteil an dem Unternehmen auf 4.164.789 Stammaktien erhöht.

Der CEO äußerte Begeisterung über die zukünftigen Perspektiven des Unternehmens und hob sein fortdauerndes Engagement hervor, wobei er anmerkte, dass sein persönliches Gesamtinvestition über $17 Millionen seit der Gründung des Unternehmens beträgt. Siokas betonte, dass Cosmos Health sich in einem transformativen Moment befindet, da das Unternehmen daran arbeitet, seine Strategie voranzutreiben, Projekte voranzubringen und seine Marken global auszuweiten.

Positive
  • CEO increases stake with $425,000 worth of shares purchase
  • CEO demonstrates confidence with total personal investment exceeding $17 million
  • Insider buying indicates management's positive outlook on company's future
Negative
  • None.

Insights

The recent accumulation of 647,809 shares by CEO Greg Siokas, valued at $425,000, translates to an average purchase price of approximately $0.66 per share. This strategic insider buying represents about 15.5% of his total beneficial ownership of 4,164,789 shares.

The purchase pattern is particularly noteworthy - six separate transactions over 32 days suggests a methodical accumulation strategy rather than a single bulk purchase. This approach often indicates a careful consideration of market dynamics and potentially helps minimize price impact while building a position.

For micro-cap healthcare companies like Cosmos Health (market cap: $19.9M), substantial insider buying can significantly influence market sentiment. The CEO's total investment of over $17M since inception represents nearly 85% of the current market capitalization, an unusually high level of insider commitment.

The timing of these purchases aligns with Cosmos Health's strategic initiatives in pharmaceutical distribution, nutraceuticals and telehealth expansion. While micro-cap healthcare stocks typically carry higher risk profiles, strong insider buying often precedes corporate developments or operational improvements that management believes will enhance shareholder value.

These transactions have occurred in a concentrated timeframe, suggesting a high conviction move rather than routine portfolio management. However, investors should note that while insider buying is generally a positive signal, it should be considered alongside other fundamental and technical factors in any investment decision.

CHICAGO, IL / ACCESS Newswire / January 21, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that its CEO, Greg Siokas, has increased his stake in the Company by acquiring a total of 647,809 common shares, valued at $425,000, across six transactions between December 20, 2024, and January 17, 2025.

As a result of these transactions, Mr. Siokas now beneficially owns 4,164,789 common shares in Cosmos Health.

Greg Siokas, CEO of Cosmos Health, stated: "I am incredibly excited about our future prospects and remain deeply committed to supporting Cosmos, having personally invested over $17 million since its inception. We are at a transformative moment, and I will continue to support our efforts as we advance our strategy and vision, driving forward our exciting projects and expanding our brands globally."

Information on Mr. Siokas's Recent Transactions:

Please refer to the filings on Form 4 filed with the SEC and available on the SEC's website for more information about the nature of the transactions, including details such as "Ownership Form", "Transaction Date", "Amount", "Price", and other relevant information regarding the shares acquired by Mr. Siokas.

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.



View the original press release on ACCESS Newswire

FAQ

How many shares did Cosmos Health CEO Greg Siokas purchase in recent transactions (COSM)?

Greg Siokas purchased 647,809 common shares valued at $425,000 through six transactions between December 20, 2024, and January 17, 2025.

What is Greg Siokas's total ownership in Cosmos Health (COSM) after recent purchases?

After the recent purchases, Greg Siokas beneficially owns 4,164,789 common shares in Cosmos Health.

How much has Greg Siokas invested in total in Cosmos Health (COSM)?

Greg Siokas has personally invested over $17 million in Cosmos Health since its inception.

When did the recent share purchases by Cosmos Health CEO occur (COSM)?

The share purchases occurred across six transactions between December 20, 2024, and January 17, 2025.

Cosmos Holdings Inc.

NASDAQ:COSM

COSM Rankings

COSM Latest News

COSM Stock Data

20.92M
18.93M
15.51%
10.28%
1.56%
Medical Distribution
Wholesale-drugs, Proprietaries & Druggists' Sundries
Link
United States of America
THESSALONIKI